Parenteral carbapenems

被引：44

作者：

Shah, P. M. ^{[1
]}

机构：

[1] Univ Frankfurt, Arzt Fuer Innere Med Mikrobiol & Infekt Sepidemio, D-6000 Biapenem Frankfurt, Germany

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2008年 / 14卷

关键词：

ertapenem; extented-spectrum beta-lactamases; imipenem; meropenem; panipenem;

D O I：

10.1111/j.1469-0691.2007.01868.x

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Among the many different structurally distinct classes of beta-lactams, the carbapenem class is regarded as that which is most potent and which has the widest spectrum of antimicrobial activity. Rapidly bactericidal, and demonstrating time-dependent killing, carbapenernes have a spectrum of antimicrobial activity that includes Gram-positive and Gram-negative aerobic and anaerobic pathogens. Their in-vitro activity includes extended-spectrum P-lactamase (ESBL)-producing pathogens and carbapenems are currently considered to be the treatment of choice for serious infections due to ESBL-producing organisms. However, isolates acquiring resistance under treatment have been reported. Imipenem, meropenern and ertapenem are licensed in the European Community and panipenem and biapenem are also available in Japan and South Korea. Other carbapenernes are under development.

引用

收藏

页码：175 / 180

页数：6

相关论文

共 48 条

[1] Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae [J].

Ahmad, M ;

Urban, C ;

Mariano, N ;

Bradford, PA ;

Calcagni, E ;

Projan, SJ ;

Bush, K ;

Rahal, JJ .

CLINICAL INFECTIOUS DISEASES, 1999, 29 (02) :352-355

[2]

ALBERTBRAUN S, 2006, CHEMOTHERAPIE J, V15, P13

[3] Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City [J].

Bradford, PA ;

Bratu, S ;

Urban, C ;

Visalli, M ;

Mariano, N ;

Landman, D ;

Rahal, JJ ;

Brooks, S ;

Cebular, S ;

Quale, J .

CLINICAL INFECTIOUS DISEASES, 2004, 39 (01) :55-60

[4] Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: Report from a Swedish study group [J].

Brismar, B ;

Akerlund, JE ;

Sjostedt, S ;

Johansson, C ;

Tornqvist, A ;

Backstrand, B ;

Bang, H ;

Andaker, L ;

Gustafsson, PO ;

Darle, N ;

Angeras, M ;

Falk, A ;

Tunevall, G ;

KasholmTengve, B ;

Skau, T ;

Nystrom, PO ;

Gasslander, T ;

Hagelback, A ;

OlssonLiljequist, B ;

Eklund, AE ;

Nord, CE .

SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1996, 28 (05) :507-512

[5]

BRYSKIER A, 1999, ANTIBIOTIQUES AGENTS, P305

[6]

Bush K, 2001, CLIN INFECT DIS, V32, P1085, DOI 10.1086/319610

[7] Emergence of imipenem resistance in Klebsiella pneumoniae owing to combination of plasmid-mediated CMY-4 and permeability alteration [J].

Cao, VTB ;

Arlet, G ;

Ericsson, BM ;

Tammelin, A ;

Courvalin, P ;

Lambert, T .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (06) :895-900

[8] First national surveillance of susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel [J].

Colodner, Raul ;

Samra, Zmira ;

Keller, Nathan ;

Sprecher, Hanna ;

Block, Colin ;

Peled, Nehama ;

Lazarovitch, Tzilia ;

Bardenstein, Rita ;

Schwartz-Harari, Orna ;

Carmeli, Yehuda .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2007, 57 (02) :201-205

[9] In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum β-lactamase [J].

Elliott, E ;

Brink, AJ ;

van Greune, J ;

Els, Z ;

Woodford, N ;

Turton, J ;

Warner, M ;

Livermore, DM .

CLINICAL INFECTIOUS DISEASES, 2006, 42 (11) :E95-E98

[10] Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum β-lactamase:: Treatment outcome of patients receiving imipenem or ciprofloxacin [J].

Endimiani, A ;

Luzzaro, F ;

Perilli, M ;

Lombardi, G ;

Colí, A ;

Tamborini, A ;

Amicosante, G ;

Toniolo, A .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (02) :243-251

← 1 2 3 4 5 →